# Fatty Acids and Inflammatory Protein Biomarkers From Coronavirus Disease 2019 Patients

## TL;DR

This study identifies changes in fatty acids and inflammatory proteins in the blood of COVID-19 patients, which could help assess disease severity and treatment options.

## Contribution

The study establishes a unique plasma signature of fatty acids and inflammatory biomarkers specific to COVID-19 patients.

## Key findings

- Fatty acid levels like arachidic and myristic acid decreased in COVID-19 patients.
- Chemokines like IP-10, MCP-1, and cytokines like IL-1 alpha were elevated in COVID-19 patients.
- Inflammatory markers such as ICAM-1 and E-selectin were higher in the plasma of infected individuals.

## Abstract

The coronavirus disease 2019 (COVID‐19) is a viral infection caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) and associated with systemic inflammation. Inflammation is an important process that follows infection and facilitates the body's innate immune response and repair of damaged tissue. Polyunsaturated fatty acids play an important role in the inflammatory process. These lipids can target transcription factors to modulate gene expression and protein function.

Here, we performed a fatty acid methyl ester (FAME) analysis and immunoassays to evaluate whether differences in basal levels of different types of biomarkers can be detected in freshly frozen plasma samples from patients with and without COVID‐19.

FAME analysis showed a decrease in arachidic acid and myristic acid, but an increase in caprylic acid, palmitic acid, and eicosenoic acid in the plasma of COVID‐19 patients compared to non‐COVID‐19 patients. Multiple chemokines including IP‐10, MCP‐1, and MIP‐1 beta were increased in the COVID‐19 group compared to the non‐COVID‐19 group. Similarly, cytokines including IL‐1 alpha and IL‐8, and cell adhesion and inflammatory response markers including ICAM‐1 and E‐selectin were greater in the plasma of COVID‐19 patients compared to non‐COVID‐19 patients.

A baseline signature of specific polyunsaturated fatty acids, cytokines, and chemokines present in the plasma after COVID‐19 viral infection may serve as biomarkers that can be useful in various applications including determination of severity of infection, indication of disease prognosis, and consideration for therapeutic options.

The coronavirus disease 2019 (COVID‐19) pandemic created the need to identify new biomarkers and drug targets. In this study, we aimed to establish a unique signature profile of specific fatty acids, cytokines, and chemokines present in the plasma after COVID‐19 viral infection to serve as novel biomarkers that can be used to determine the severity of infection, disease prognosis, and consideration for therapeutic options.